In re Magnolia Medical Technologies, Inc.

The case In re Magnolia Medical Technologies, Inc. concerns an appeal from a Patent Trial and Appeal Board (PTAB) decision to the U.S. Court of Appeals for the Federal Circuit. The appellant, Magnolia Medical Technologies, Inc., is an operating company based in Seattle, Washington, specializing in the development, manufacture, and marketing of blood collection systems. These systems, notably their Steripath® Initial Specimen Diversion Device® (ISDD®) platform, are designed to improve diagnostic accuracy for sepsis testing by reducing blood culture contamination, a significant issue in healthcare that can lead to misdiagnosis and unnecessary antibiotic use.

This case is not a direct patent infringement litigation, but rather a patent validity challenge originating from an ex parte reexamination of U.S. Patent No. 10,039,483 (the '483 patent). The '483 patent covers a blood sequestration device designed to prevent skin microbes from contaminating blood samples during collection. Specifically, claim 1 of the patent requires a housing with a fluid reservoir to receive an initial volume of blood and a pathway that allows a subsequent volume of blood to bypass this reservoir and flow directly to a sample collection outlet. A third party requested the ex parte reexamination, asserting that claim 1 of the '483 patent was anticipated by U.S. Patent No. 6,013,037, referred to as the "Brannon" patent, which describes a syringe for collecting multiple blood samples while reducing contamination and hemolysis.

The procedural posture involved Magnolia Medical Technologies appealing an examiner's rejection of claim 1 of the '483 patent to the PTAB, which affirmed the rejection, finding the claim anticipated by the Brannon patent. Magnolia Medical then appealed this PTAB decision to the Federal Circuit (Case No. 25-1961), which has exclusive appellate jurisdiction over patent matters. On July 9, 2026, the Federal Circuit affirmed the PTAB's decision, upholding the finding that claim 1 of the '483 patent was anticipated and thus unpatentable. This case is notable as an operating company's challenge to the invalidation of a key claim in its foundational intellectual property portfolio, which could impact its competitive standing in the medical device market for sepsis diagnostics. While Magnolia Medical Technologies has been involved in other patent disputes, including asserting the '483 patent in district court against Kurin, Inc., and petitioning for IPR against Kurin's patents, this specific Federal Circuit decision In re Magnolia Medical Technologies, Inc. focuses solely on the validity of its own '483 patent claim through reexamination.

The legal journey of U.S. Patent 10,039,483, owned by Magnolia Medical Technologies, Inc., involved both district court patent infringement litigation and a separate ex parte reexamination proceeding at the U.S. Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB), culminating in two distinct appeals to the U.S. Court of Appeals for the Federal Circuit.

Key Legal Developments and Outcome

Initial District Court Patent Infringement Litigation: Magnolia Medical Technologies, Inc. v. Kurin, Inc.

• Filing & Initial Pleadings (2019): Magnolia Medical Technologies, Inc. (Magnolia) initiated a patent infringement lawsuit against Kurin, Inc. (Kurin) in the U.S. District Court for the District of Delaware (Case No. 19-cv-00097-CFC-CJB). The suit, filed around March 2019, asserted infringement of U.S. Patent Nos. 10,039,483 (the '483 patent) and 9,855,001 (the '001 patent), among others initially.
• Claim Construction (Markman) (May 20, 2020): The district court conducted a claim construction analysis, including a determination that the term "diverter" in the '001 patent should be construed as a means-plus-function term. Following this construction, the parties stipulated to non-infringement of the '001 patent.
• Trial Events & Jury Verdict (Undated, prior to May 2024): The case proceeded to a jury trial focusing solely on the '483 patent. The jury found that Kurin infringed the asserted claims of the '483 patent.
• Post-Trial Motions – Judgment as a Matter of Law (JMOL) (May 14, 2024): The district court granted Kurin's post-trial motion for judgment as a matter of law (JMOL), ruling that Kurin did not infringe the '483 patent. The court determined that claim 1 of the '483 patent required separate structures for a "seal member" and a "vent," which Kurin's accused product, the Kurin Lock, did not possess, as its single porous plug performed both functions. Final judgment was entered in favor of Kurin.
• Appeal to Federal Circuit (Case No. 24-2001) & Outcome (March 6, 2026): Magnolia appealed the district court's JMOL decision to the U.S. Court of Appeals for the Federal Circuit (Case No. 24-2001). On March 6, 2026, the Federal Circuit affirmed the district court's judgment of non-infringement regarding the '483 patent and upheld the claim construction for the '001 patent.

Parallel USPTO Ex Parte Reexamination Proceeding

• Request for Ex Parte Reexamination (Prior to May 3, 2023): A third party, identified as Kurin, Inc., requested an ex parte reexamination of U.S. Patent 10,039,483.
• Reexamination Grant (May 3, 2023): The USPTO granted the request for reexamination, finding "Substantial New Questions of Patentability" meriting review.
• Examiner's Rejection (Undated): An examiner subsequently rejected claim 1 of the '483 patent, finding it anticipated by U.S. Patent 6,013,037, referred to as "Brannon."
• PTAB Appeal & Affirmance (Undated, prior to 2025): Magnolia Medical Technologies appealed the examiner's rejection to the Patent Trial and Appeal Board (PTAB), which affirmed the rejection, agreeing that claim 1 was anticipated by the '037 patent.

Federal Circuit Appeal from PTAB Ex Parte Reexamination: In re Magnolia Medical Technologies, Inc. (Case No. 25-1961)

• Filing of Appeal (2025): Magnolia Medical Technologies, Inc. filed an appeal with the U.S. Court of Appeals for the Federal Circuit (Case No. 25-1961) to challenge the PTAB's decision affirming the rejection of claim 1 of the '483 patent from the ex parte reexamination.
• Final Disposition – Judgment - Affirmed (July 9, 2026): On July 9, 2026, the Federal Circuit issued a decision in In re Magnolia Medical Technologies, Inc., affirming the PTAB's decision. The Federal Circuit upheld the PTAB's finding that claim 1 of U.S. Patent 10,039,483 was anticipated by U.S. Patent 6,013,037 and is therefore unpatentable. This ruling invalidates claim 1 of the '483 patent. The court found the Board's findings regarding the "fluid reservoir limitation" and the "bypass limitation" were supported by substantial evidence.

Parallel PTAB IPR/PGR Proceedings (Not the subject of Federal Circuit 25-1961)

While the Federal Circuit Case 25-1961 originated from an ex parte reexamination, it is worth noting that Kurin, Inc. did attempt to file Inter Partes Review (IPR) petitions related to Magnolia's patents. For example, in IPR2026-00097, Kurin challenged a different patent (U.S. Patent 12,138,052 B1) but the petition was discretionarily denied institution by the USPTO Director on May 14, 2026. This denial was based on Kurin having already litigated similar patent validity grounds in district court. These IPR proceedings, however, are distinct from the ex parte reexamination that led to the Federal Circuit appeal in Case No. 25-1961.

Based on the available search results, the counsel of record representing Magnolia Medical Technologies, Inc. in In re Magnolia Medical Technologies, Inc., Federal Circuit Case 25-1961, cannot be definitively identified.

While the Federal Circuit issued its decision in Case 25-1961 on July 9, 2026, affirming a Patent Trial and Appeal Board (PTAB) decision regarding U.S. Patent 10,039,483, the provided excerpts of the opinion do not include the list of appearing counsel.

It is important to distinguish this case from another Federal Circuit appeal involving Magnolia Medical Technologies, Inc., specifically Magnolia Medical Technologies, Inc. v. Kurin, Inc., Case 2024-2001, which was decided on March 6, 2026. In that infringement case, the following counsel represented Magnolia Medical Technologies, Inc.:

• Mark Andrew Perry (Lead Counsel)
  • Firm: Weil, Gotshal & Manges LLP
  • Office Location: Washington, D.C.
  • Note: Argued for plaintiff-appellant in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (Fed. Cir. 2024-2001).
• Rocco Joseph Recce
  • Firm: Weil, Gotshal & Manges LLP
  • Office Location: New York, NY
  • Note: Also represented plaintiff-appellant in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (Fed. Cir. 2024-2001).
• Micah Block
  • Firm: Weil, Gotshal & Manges LLP
  • Note: Also represented plaintiff-appellant in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (Fed. Cir. 2024-2001).

However, these attorneys are associated with the infringement case (2024-2001) and not explicitly with the ex parte reexamination appeal (25-1961) as requested. The available search results do not provide the specific counsel for the In re Magnolia Medical Technologies, Inc. case (25-1961).

In In re Magnolia Medical Technologies, Inc., Federal Circuit case number 25-1961, the proceeding is an appeal from a Patent Trial and Appeal Board (PTAB) decision in an ex parte reexamination, not a patent infringement case. In this type of appeal, Magnolia Medical Technologies, Inc. is the appellant (patent owner), and the appellee is the Director of the U.S. Patent and Trademark Office (USPTO). The Federal Circuit affirmed the PTAB's decision on July 9, 2026, finding claim 1 of US Patent 10039483 unpatentable.

As the case was resolved by a judgment of affirmance (likely a Rule 36 affirmance, which typically does not include a detailed written opinion or explicitly name counsel in public summaries), specific individual attorneys representing the Director of the USPTO are not readily identified in the publicly available information for this particular docket.

Generally, the Director of the USPTO is represented by attorneys from the Office of the Solicitor of the USPTO. While individual names are not available for this specific ruling, their role is to defend the decisions of the PTAB before the Federal Circuit.